Coronavirus: working together on a solution

Posted on February 7, 2020

While the public health risk in Canada is low, the global outbreak of the novel coronavirus (nCov-2019) is an issue of growing concern around the world.

The innovative pharmaceutical industry is working around the clock to find solutions to treat those infected by the virus and to prevent it from spreading.

The following are but a few examples of how our member companies are engaged in combatting the coronavirus:

Roche is working with the Chinese government and health authorities to ensure access to proper screening and healthcare for those infected with the virus. In addition, the company has donated diagnostic testing equipment, medical supplies, as well as provided financial support for China’s Hubei Province.

Johnson & Johnson (J&J) has begun research into a vaccine, leveraging the same innovative technology used for the company’s investigational Ebola vaccine. Janssen, the pharmaceutical arm of J&J, has donated medicines for use in laboratory-based investigations to support efforts in finding a solution against coronavirus.

Abbvie has also shipped medicines to China and Merck is reviewing research on repurposing drug compounds to fight the virus.

Sanofi has plans to announce a new coronavirus initiative within the next two weeks and is already sharing its expertise and data acquired from other outbreaks with the Coalition for Epidemic Preparedness Innovations (CEPI), which is working with biotech businesses in developing a vaccine candidate for the virus.

GlaxoSmithKline  has also been working with CEPI and recently announced a new collaboration aimed at helping the global effort to develop a vaccine. The company will make its established pandemic vaccine adjuvant platform technology available to enhance this development.

Pfizer has provided financial support to its global partners who have shipped supplies to hospitals in China.

What does this mean? Working collaboratively, governments, other life sciences organizations, and the biopharmaceutical industry are hopeful that a vaccine will be in human trials by April.

Our industry remains dedicated to the discovery, development and delivery of life saving medicines and treatments.

For more information, please visit the following links:

Leave a Reply

Your email address will not be published. Required fields are marked *